TD Asset Management Inc Reduces Stock Position in Prestige Consumer Healthcare Inc. $PBH

TD Asset Management Inc lowered its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 33.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,600 shares of the company’s stock after selling 9,400 shares during the quarter. TD Asset Management Inc’s holdings in Prestige Consumer Healthcare were worth $1,485,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Maseco LLP purchased a new stake in Prestige Consumer Healthcare in the second quarter worth approximately $27,000. Geneos Wealth Management Inc. boosted its holdings in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. Costello Asset Management INC bought a new position in Prestige Consumer Healthcare in the first quarter worth approximately $112,000. Finally, GAMMA Investing LLC raised its position in Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock worth $162,000 after acquiring an additional 496 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Ratings Changes

PBH has been the topic of several recent research reports. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Oppenheimer decreased their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $90.60.

Prestige Consumer Healthcare Stock Up 1.4%

Shares of PBH stock opened at $63.37 on Thursday. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 1.98 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a one year low of $60.15 and a one year high of $90.04. The company’s fifty day moving average price is $64.16 and its 200-day moving average price is $74.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm’s revenue for the quarter was down 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.